| Literature DB >> 34885893 |
Yue-Chiun Li1, Nguyen Thi Ngan2, Kun-Ching Cheng3, Tsong-Long Hwang4,5,6, Tran Dinh Thang2, Nguyen Ngoc Tuan2, Mei-Lin Yang1, Ping-Chung Kuo1, Tian-Shung Wu1.
Abstract
It is reported that various fungi have been used for medicine and edible foods. The tropical Trametes genus is popular and well-known in Vietnam for its health effects and bioactivities. In this study, the fruiting bodies of the edible fungi T. cubensis and T. suaveolens were collected in Vietnam. The preliminary bioactivity screening data indicated that the methanol extracts of the fruiting bodies of T. cubensis and T. suaveolens displayed significant inhibition of superoxide anion generation and elastase release in human neutrophils. Therefore, the isolation and characterization were performed on these two species by a combination of chromatographic methods and spectrometric analysis. In total, twenty-four compounds were identified, and among these (1-3) were characterized by 1D-, 2D-NMR, and HRMS analytical data. In addition, the anti-inflammatory potentials of some purified compounds were examined by the cellular model for the inhibition of superoxide anion generation and elastase release in human neutrophils. Among the isolated compounds, (5,14), and (19) displayed significant anti-inflammatory potential. As the results suggest, the extracts and isolated compounds from T. cubensis and T. suaveolens are potential candidates for the further development of new anti-inflammatory lead drugs or natural healthy foods.Entities:
Keywords: Trametes cubensis; Trametes suaveolens; anti-inflammatory; elastase release; superoxide anion generation
Mesh:
Substances:
Year: 2021 PMID: 34885893 PMCID: PMC8659016 DOI: 10.3390/molecules26237311
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Fruiting bodies of (a) T. cubensis and (b) T. suaveolens.
Preliminary bioactivity screening of fruiting bodies of T. cubensis and T. suaveolens on superoxide anion generation and elastase release by human neutrophils in response to fMLF/CB.
| Samples | Superoxide Anion | Elastase Release | ||
|---|---|---|---|---|
| Inhibition (%) a | Promotion (%) b | Inhibition (%) | Promotion (%) | |
|
| – c | 50.9 ± 5.1 *** | – | 98.5 ± 7.7 |
|
| 15.2 ± 3.8 * | – | 1.9 ± 4.7 | – |
|
|
| |||
| LY294002 e | 0.4 ± 0.02 *** | – | 1.5 ± 0.3 *** | – |
a Inhibitory percentage at 10 μg/mL sample concentration. Results are presented as mean ± S.E.M. (n = 3 or 4). * p < 0.05, *** p < 0.001 compared with the control value. b Promotion of sample on superoxide anion generation and elastase release as compared to fMLF/CB (100%). c Not determined. d 50% Inhibitory concentration (IC50). e A phosphatidylinositol-3-kinase inhibitor was used as a positive control for superoxide anion generation and elastase release.
Figure 2Structures and key HMBC correlations (→) of compounds 1–3.
1H and 13C NMR spectroscopic data of compounds 1–3.
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| 1 | 1.80 (1H, m) | 38.8 | 1.75 (1H, m) | 39.2 | 1.76 (1H, m) | 38.9 |
| 2 | 1.65 (2H, m) | 32.4 | 1.52 (2H, m) | 33.1 | 1.64 (2H, m) | 32.4 |
| 3 | 3.16 (1H, dd, | 79.6 | 3.15 (1H, dd, | 79.7 | 3.16 (1H, dd, | 79.6 |
| 4 | – | 39.9 | – | 39.9 | – | 39.9 |
| 5 | 1.05 (1H, m) | 51.8 | 1.03 (1H, m) | 51.9 | 1.03 (1H, m) | 51.9 |
| 6 | 2.20 (2H, m) | 28.5 | 2.18 (2H, m) | 28.5 | 1.62 (1H, m) | 28.5 |
| 7 | 1.65 (2H, m) | 28.2 | 1.62 (2H, m) | 28.3 | 2.19 (1H, m) | 28.2 |
| 8 | – | 135.4 | – | 135.6 | – | 135.4 |
| 9 | – | 136.2 | – | 136.2 | – | 136.2 |
| 10 | – | 38.3 | – | 38.3 | – | 38.3 |
| 11 | 1.60 (1H, m) | 19.4 | 1.54 (1H, m) | 19.5 | 1.55 (1H, m) | 19.4 |
| 12 | 1.29 (2H, m) | 30.6 | 1.31 (2H, m) | 30.8 | 1.30 (2H, m) | 30.5 |
| 13 | – | 52.6 | – | 52.6 | – | 52.6 |
| 14 | – | 46.0 | – | 46.1 | – | 46.1 |
| 15 | 4.19 (1H, dd, | 73.7 | 4.16 (1H, dd, | 74.3 | 4.18 (1H, dd, | 73.9 |
| 16 | 2.05 (2H, m) | 21.7 | 1.99 (2H, m) | 21.8 | 1.99 (2H, m) | 21.8 |
| 17 | 2.20 (1H, m) | 47.1 | 2.18 (1H, m) | 47.0 | 2.19 (1H, m) | 47.1 |
| 18 | 1.00 (3H, s) | 19.6 | 0.99 (3H, s) | 19.6 | 1.00 (3H, s) | 19.6 |
| 19 | 0.83 (3H, s) | 16.8 | 0.85 (3H, s) | 16.2 | 0.84 (3H, s) | 16.2 |
| 20 | 2.20 (1H, m) | 49.0 | 2.18 (1H, m) | 47.2 | 2.19 (1H, m) | 51.1 |
| 21 | – | 180.2 | – | 180.4 | – | 178.6 |
| 22 | 1.25 (1H, m) | 37.0 | 1.20 (1H, m) | 37.1 | 1.21 (1H, m) | 37.0 |
| 23 | 2.20 (2H, m) | 27.5 | 2.18 (2H, m) | 28.3 | 2.37 (2H, m) | 28.2 |
| 24 | 6.74 (1H, t, | 142.5 | 6.45 (1H, td, | 137.2 | 6.63 (1H, t, | 156.6 |
| 25 | – | 129.8 | – | 134.7 | – | 140.6 |
| 26 | – | 171.8 | – | 178.1 | 9.36 (1H, s) | 197.3 |
| 27 | 1.79 (3H, s) | 12.5 | 1.79 (3H, s) | 13.9 | 1.71 (3H, s) | 9.1 |
| 28 | 0.80 (3H, s) | 16.2 | 0.80 (3H, s) | 17.0 | 0.80 (3H, s) | 16.9 |
| 29 | 0.99 (3H, s) | 28.6 | 0.98 (3H, s) | 28.6 | 0.98 (3H, s) | 28.6 |
| 30 | 0.93 (3H, s) | 17.8 | 0.93 (3H, s) | 17.9 | 0.93 (3H, s) | 17.8 |
1H- and 13C-NMR data (δ in ppm) were measured in CD3OD at 400 and 100 MHz, respectively.
Figure 3Key NOESY correlations (↔) of compounds 1–3.
Inhibitory effects of isolated compounds on superoxide anion generation and elastase release by human neutrophils in response to fMLF/CB.
| Compound | Superoxide Anion | Elastase Release | ||
|---|---|---|---|---|
| IC50 (μM) a | Inh% b | IC50 (μM) | Inh% | |
|
| – c | 22.4 ± 3.1 ** | – | 25.4 ± 6.2 * |
|
| – | 8.7 ± 4.3 | – | 8.6 ± 1.1 ** |
|
| 2.3 ± 0.2 | 100.2 ± 1.1 *** | 5.0 ± 0.3 | 88.2 ± 3.4 *** |
|
| – | – | – | 35.1 ± 4.8 ** |
|
| – | -0.7 ± 1.5 | – | 3.1 ± 1.6 |
|
| – | -1.0 ± 2.6 | – | 3.7 ± 3.2 |
|
| – | 26.0 ± 7.8 * | – | 5.3 ± 4.0 |
|
| 3.7 ± 0.6 | 86.7 ± 3.9 *** | 5.2 ± 0.4 | 86.9 ± 6.3 *** |
|
| – | 3.9 ± 4.4 | – | 12.4 ± 0.8 *** |
|
| 4.1 ± 0.4 | 84.1 ± 7.0 *** | 4.3 ± 0.2 | 94.3 ± 3.8 *** |
|
| – | 13.2 ± 3.1 * | – | 15.6 ± 2.3 ** |
| LY294002 d | 1.1 ± 0.3 | 100.6 ± 1.0 *** | 3.2 ± 1.0 | 76.7 ± 6.8 *** |
Results are presented as mean ± SEM (n = 3,4). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control (DMSO). a Concentration necessary for 50% inhibition (IC50). b Percentage of inhibition (Inh%) at 10 μM concentration. c Not determined. d A phosphatidylinositol-3-kinase inhibitor was used as a positive control.
Figure 4Chemical structures of 5, 14, and 19.
Binding energies of compounds 5, 14, and 19, and LY294002 calculated in silico.
| Compound | Affinity |
|---|---|
|
| −6.9 |
|
| −7.4 |
|
| −7.0 |
| LY294002 | −6.0 |
Figure 5In silico modeling of (A) LY294002, (B) 5, (C) 14, and (D) 19 docking into the human neutrophil elastase.